Why sign up? Because transforming drug development is not just our goal—it’s our obsession. If it’s yours too, then be the first to know of new insights and join us in pushing the boundaries of science.

Early Clinical

Latest resources

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients

Adaptive clinical trials in oncology: Meeting the challenge of Project Optimus

Certara Solutions to Transform Drug Discovery and Development for Good

Featured resource

Transform PK/PD Workflows with Automation and Integration

Upcoming early clinical webinars

Explore Smarter, Faster PK/PD with Phoenix

Certara’s Simcyp Educational Webinar Series Part 4: Changes in Drug Absorption after Meals and the Reality of Prediction Using Modeling Approaches [in Japanese]

Simcyp® Simulator Version 25: Streamline Drug Development with Regulatory-Compliant PBPK

Latest early clinical blogs

Machine Learning for PK/PD Modeling in Drug Development

How the US FDA MIDD paired pilot program helps sponsors

Measuring metabolites in index clinical DDI studies

Why FDA’s omaveloxolone approval for Friedreich’s ataxia matters

Key development considerations for cell therapies

De-risking Drug Development: Key Chemistry, Manufacturing, and Controls (CMC) and Physiologically Based Pharmacokinetic (PBPK) Approaches in Early Development

Meet our experts at the following events

ICoP 2026 India

MVA Oncology Network

16th Annual World ADC London 2026

All early clinical resources

Model-based Development of Gemcabene, a New Lipid-altering Agent

Model-based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model

Modelling Approaches to Dose Estimation in Children

Does Neuromuscular Electrical Stimulation Strengthen the Quadriceps Femoris? A Systematic Review of Randomized Controlled Trials

Population Pharmacokinetics of Olmesartan Following Oral Administration of Its Prodrug, Olmesartan Medoxomil: In Healthy Volunteers and Hypertensive Patients

In Silico Simulations to Assess the In Vivo Consequences of In Vitro Metabolic Drug-drug Interactions

Assessment of In Vivo CYP2D6 Activity: Differential Sensitivity of Commonly Used Probes to Urine pH

Predicting the Clearance of CYP2C9 Substrates

Cytochrome P450 3A Expression and Activity in the Human Small Intestine

Pharmacogenetics—Expectations and Reality

Prediction of Clearance from Recombinantly Expressed CYPs: Intersystem Extrapolation Factor (ISEF)

The Effects of Dose Staggering on Metabolic Drug-drug Interactions

Newsletter sign up

Quick links

Solutions

Contact